Skip to content
  • About
    • Leaders
  • Our Science
    • Pipeline
    • Nemvaleukin Alfa
    • MURA-7012
    • MURA-8518
  • Publications
Mural Oncology logo
  • Clinical Trials
  • Investors & News
    • Press Releases
    • Events & Presentations
    • Financials & Filings
    • Stock Information
    • Governance
  • Careers
    • Job Opportunities
  • Search
Mural Oncology logo
  • Home
  • About
    • Leaders
  • Our Science
    • Pipeline
    • Nemvaleukin Alfa
    • MURA-7012
    • MURA-8518
  • Clinical Trials
  • Publications
  • Investors & News
    • Press Releases
    • Events & Presentations
    • Financials & Filings
    • Stock Information
    • Governance
  • Careers
    • Job Opportunities
  • Home
  • About
    • Leaders
  • Our Science
    • Pipeline
    • Nemvaleukin Alfa
    • MURA-7012
    • MURA-8518
  • Clinical Trials
  • Publications
  • Investors & News
    • Press Releases
    • Events & Presentations
    • Financials & Filings
    • Stock Information
    • Governance
  • Careers
    • Job Opportunities

MURA-8518
Preclinical

By Mural Oncology | September 20, 2024

MURA-8518 is a half-life extended, binding protein-resistant IL-18.

>> More About MURA-8518

Recent Posts

    Recent Comments

    No comments to show.
    • About
    • Our Science
    • Publications
    • Clinical Trials
    • Investors & News
    • Careers
    • Contact
    • About
    • Our Science
    • Publications
    • Clinical Trials
    • Investors & News
    • Careers
    • Contact

    © 2025 Mural Oncology. All Rights Reserved.

    Mural Oncology logo white
    • Privacy Policy
    • Terms of Use
    • Site Map
    • Privacy Policy
    • Terms of Use
    • Site Map
    Mural Oncology on Linkedin Mural Oncology on Twitter